Literature DB >> 22335314

Acute respiratory distress syndrome: diagnosis and management.

Aaron Saguil1, Matthew Fargo.   

Abstract

Acute respiratory distress syndrome manifests as rapidly progressive dyspnea, tachypnea, and hypoxemia. Diagnostic criteria include acute onset, profound hypoxemia, bilateral pulmonary infiltrates, and the absence of left atrial hypertension. Acute respiratory distress syndrome is believed to occur when a pulmonary or extrapulmonary insult causes the release of inflammatory mediators, promoting neutrophil accumulation in the microcirculation of the lung. Neutrophils damage the vascular endothelium and alveolar epithelium, leading to pulmonary edema, hyaline membrane formation, decreased lung compliance, and difficult air exchange. Most cases of acute respiratory distress syndrome are associated with pneumonia or sepsis. It is estimated that 7.1 percent of all patients admitted to an intensive care unit and 16.1 percent of all patients on mechanical ventilation develop acute lung injury or acute respiratory distress syndrome. In-hospital mortality related to these conditions is between 34 and 55 percent, and most deaths are due to multiorgan failure. Acute respiratory distress syndrome often has to be differentiated from congestive heart failure, which usually has signs of fluid overload, and from pneumonia. Treatment of acute respiratory distress syndrome is supportive and includes mechanical ventilation, prophylaxis for stress ulcers and venous thromboembolism, nutritional support, and treatment of the underlying injury. Low tidal volume, high positive end-expiratory pressure, and conservative fluid therapy may improve outcomes. A spontaneous breathing trial is indicated as the patient improves and the underlying illness resolves. Patients who survive acute respiratory distress syndrome are at risk of diminished functional capacity, mental illness, and decreased quality of life; ongoing care by a primary care physician is beneficial for these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22335314

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  24 in total

1.  NOS-2 Inhibition in Phosgene-Induced Acute Lung Injury.

Authors:  Piotr T Filipczak; Albert P Senft; JeanClare Seagrave; Waylon Weber; Philip J Kuehl; Laura E Fredenburgh; Jacob D McDonald; Rebecca M Baron
Journal:  Toxicol Sci       Date:  2015-04-13       Impact factor: 4.849

2.  Cytoskeletal mechanisms regulating vascular endothelial barrier function in response to acute lung injury.

Authors:  Anita Kása; Csilla Csortos; Alexander D Verin
Journal:  Tissue Barriers       Date:  2015-04-03

3.  Lugrandoside attenuates LPS-induced acute respiratory distress syndrome by anti-inflammation and anti-apoptosis in mice.

Authors:  Chengbao Li; Ying Huang; Xueya Yao; Baoji Hu; Suzhen Wu; Guannan Chen; Xin Lv; Fubo Tian
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

4.  An Improved Method for Rapid Intubation of the Trachea in Mice.

Authors:  Tyler C Vandivort; Dowon An; William C Parks
Journal:  J Vis Exp       Date:  2016-02-22       Impact factor: 1.355

5.  Examination of Taurine Chloramine and Taurine on LPS-Induced Acute Pulmonary Inflammatory in Mice.

Authors:  Khanh Hoang Nguyen; Shigeru Murakami; Stephen W Schaffer; Takashi Ito
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

6.  FGF1 alleviates LPS-induced acute lung injury via suppression of inflammation and oxidative stress.

Authors:  Qhaweni Dhlamini; Wei Wang; Guifeng Feng; Aiping Chen; Lei Chong; Xue Li; Quan Li; Jin Wu; Depu Zhou; Jie Wang; Hailin Zhang; Jin-San Zhang
Journal:  Mol Med       Date:  2022-06-28       Impact factor: 6.376

7.  Ascorbic Acid Attenuates Hyperoxia-Compromised Host Defense against Pulmonary Bacterial Infection.

Authors:  Vivek S Patel; Vaishali Sampat; Michael Graham Espey; Ravikumar Sitapara; Haichao Wang; Xiaojing Yang; Charles R Ashby; Douglas D Thomas; Lin L Mantell
Journal:  Am J Respir Cell Mol Biol       Date:  2016-10       Impact factor: 6.914

8.  Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels.

Authors:  Martha L Bustos; Luai Huleihel; Ernest M Meyer; Albert D Donnenberg; Vera S Donnenberg; Joseph D Sciurba; Lyle Mroz; Bryan J McVerry; Bryon M Ellis; Naftali Kaminski; Mauricio Rojas
Journal:  Stem Cells Transl Med       Date:  2013-10-02       Impact factor: 6.940

9.  The art of self-knowledge and deduction in clinical practice.

Authors:  Fergus William Gardiner
Journal:  Ann Med Surg (Lond)       Date:  2016-07-13

10.  Asialoerythropoietin ameliorates bleomycin-induced acute lung injury in rabbits by reducing inflammation.

Authors:  Akinaga Sonoda; Norihisa Nitta; Keiko Tsuchiya; Hideji Otani; Shobu Watanabe; Kenichi Mukaisho; Yuki Tomozawa; Yukihiro Nagatani; Shinichi Ohta; Masashi Takahashi; Kiyoshi Murata
Journal:  Exp Ther Med       Date:  2014-09-12       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.